Q-omics provides the consensus-scored ARL9 profile across patient tissues and cancer cell-line models. ARL9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARL9 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, ARL9 RNA expression shows 14,108 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where ARL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL9 survival associations across molecular data types. ARL9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL9 RNA expression–survival associations across cancer types. High ARL9 expression shows unfavorable associations in KIRC, UVM, LGG, STAD, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARL9 RNA expression.
This table summarizes ARL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL9 shows higher tumor expression in LUSC, LUAD, HNSC, STAD, COAD and CHOL. The LUSC box plot shows higher ARL9 RNA expression in tumor versus normal tissue (log2 FC = +1.785, t-test p < 0.001).
This table shows molecular features associated with ARL9 in patient tissues and cancer cell lines. In patient samples, ARL9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
